Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
56.11
-0.52 (-0.92%)
Jul 23, 2026, 12:29 PM EDT - Market open
Forte Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
A phase I-B, placebo-controlled trial of FB102 in vitiligo showed robust, statistically significant improvements in facial repigmentation, especially in patients with extensive disease, with effects deepening even after treatment cessation. The dual IL-2/IL-15 blockade mechanism yielded favorable efficacy and safety compared to JAK inhibitors, supporting further development.
Fiscal Year 2025
-
FB102, an antibody targeting CD122, showed statistically significant protection against gluten-induced gut inflammation and symptoms in a phase 1B celiac disease trial, with a favorable safety profile. A phase 2 trial will expand on these findings using composite endpoints, with data expected in 2026.